Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | WDR5 | P61964 | 2/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | IDE | P14735 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29752552 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL8081113 | 0.88 | ALDH1A1 (0.38) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL2994158 | 0.88 | ALDH1A1 (0.42) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL8503271 | 0.87 | ALDH1A1 (0.40) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL2992903 | 0.86 | LMNA (0.39) | ALDH1A1KMT2ACYP2C9LMNAMAPT | |
| SCHEMBL31515431 | 0.86 | ALDH1A1 (0.41) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL2991805 | 0.86 | IKBKB (0.40) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL1735008 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL1733369 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 | |
| SCHEMBL1734018 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2ACYP2C9WDR5DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111704573-B | Preparation method of rabeprazole chloride and intermediate thereof | 珠海润都制药股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-111704573-A | Preparation method of rabeprazole chloride and intermediate thereof | 珠海润都制药股份有限公司 | 2020-09-25 | — | — | CN | claimed |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-111704573-B | Preparation method of rabeprazole chloride and intermediate thereof | 珠海润都制药股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11253503-B2 | Inhibitors of SARM1 NADase activity and uses thereof | WASHINGTON UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| CN-111704573-A | Preparation method of rabeprazole chloride and intermediate thereof | 珠海润都制药股份有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20200129493-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-04-30 | — | — | US | disclosed |
| WO-2018057989-A1 | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2009116072-A2 | PROCESS FOR PREPARATION OF PYRIDINYLMETHYLSULPHINYL BENZIMIDAZOLE COMPOUNDS AND PYRIDINE INTERMEDIATES | IPCA LABORATORIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| EP-2022789-A1 | Process for the preparation of a gastric acid secretion inhibitor | Farmaprojects, S.A. (ES) | 2009-02-11 | — | — | EP | disclosed |
| WO-2001004109-A1 | PROCESS FOR THE PRODUCTION OF 2-(2-PYRIDINYLMETHYLSULPHINYL)-1H-BENZIMIDAZOLES | QUIMICA SINTETICA, S.A. (ES) | 2001-01-18 | — | — | WO | disclosed |
| US-5998445-A | PEPTIC ULCERS | EISAI CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| US-5840910-A | Pyridine derivatives having anti-ulcerative activity | ESAI CO., LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0268956-B2 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | EISAI CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| EP-0786461-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| EP-0654471-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and process for preparing the same | Eisai Co., Ltd. (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0475456-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-5045552-A | Pyridine derivatives having anti-ulcerative activity | EISAI CO., LTD. (JP) | 1991-09-03 | — | — | US | disclosed |
| EP-0268956-A2 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129493-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | SARM1, NADK, NNMT | ALDH1A1 1659/4885KMT2A 2098/4885CYP2C9 4424/4885 |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | SARM1, NADK, NNMT | ALDH1A1 1659/4885KMT2A 2098/4885CYP2C9 4424/4885 |
| US-11253503-B2 | Inhibitors of SARM1 NADase activity and uses thereof | SARM1, NADK, NNMT | ALDH1A1 1659/4885KMT2A 2098/4885CYP2C9 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.